Table of Contents
ISRN Oncology
Volume 2011, Article ID 390676, 5 pages
Review Article

Anti-Inflammatory Drugs Reduce the Risk of Hepatocellular Carcinoma Development

1Department of Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
2Tarao Clinic, 2-58-6 Futamatagawa, Asahi-ku, Yokohama 241-0821, Japan

Received 4 April 2011; Accepted 18 May 2011

Academic Editor: N. T. Telang

Copyright © 2011 Yasushi Rino and Kazuo Tarao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Nowadays, patients with chronic hepatitis C in all countries are generally treated with interferon (IFN), and more than 50% of patients become HCV-RNA negative following PEG-IFN plus ribavirin therapy, but unfortunately, the IFN therapy is not effective in about 70% of patients with HCV-associated LC. In Japan, HCC actually develops in about 7% of those patients every year. A strategy for preventing HCC development other than IFN therapy is, therefore, urgently needed for those patients. We reported that the recurrence rate and the development of HCC was more rapid in the high serum ALT level (>80 IU) patients with HCV-associated LC. Sho-saiko-to, Juzen-taiho-to, and stronger-neo minophagen C are herbal medicines used in Japan to treat chronic viral liver diseases, and they work by reducing inflammatory processes and controlling ALT levels. Aggressive reduction therapy for ALT levels in HCV-LC patients could significantly prevent HCC development.